Author:
Hasinoff Brian B.,Herman Eugene H.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology
Reference23 articles.
1. Swain, S. M., & Vici, P. (2004). The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. Journal of Cancer Research and Clinical Oncology, 130, 1–7.
2. Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., & Cairo, G. (2004). Doxorubicin cardiotoxicity and the control of iron metabolism: Quinone-dependent and independent mechanisms. Methods in Enzymology, 378, 340–361.
3. Herman, E. H., & Ferrans, V. J. (1990). Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treatment Reviews, 17, 155–160.
4. Hasinoff, B. B., Hellmann, K., Herman, E. H., & Ferrans, V. J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Current Medicinal Chemistry, 5, 1–28.
5. Diop, N. K., Vitellaro, L. K., Arnold, P., Shang, M., & Marusak, R. A. (2000). Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: Solid state structure, solution thermodynamics, and DNA cleavage activity. Journal of Inorganic Biochemistry, 78, 209–216.
Cited by
108 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献